Lucid Diagnostics (LUCD) has released an update to notify the public and investors about the unregistered sales of equity securities.
Lucid Diagnostics Inc. and its parent company PAVmed Inc. have agreements wherein PAVmed manages certain activities for Lucid, provides resources, and covers payroll and benefit expenses. PAVmed can opt to be compensated in Lucid’s common stock according to the agreement terms. On January 26, 2024, PAVmed chose to receive $4,675,256 in fees and reimbursements through the issuance of 3,331,771 Lucid common stock shares. This amount is equal to what PAVmed will distribute to its stockholders by February 15, 2024.
For further insights into LUCD stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
